BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34762492)

  • 1. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
    Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
    Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas.
    Rahm V; Boxheimer L; Bruehlmeier M; Berberat J; Nitzsche EU; Remonda L; Roelcke U
    J Nucl Med; 2014 Apr; 55(4):546-50. PubMed ID: 24566001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
    Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma.
    Martucci M; Ferranti AM; Schimperna F; Infante A; Magnani F; Olivi A; D'Alessandris QG; Gessi M; Chiesa S; Mazzarella C; Russo R; Giordano C; Gaudino S
    Neuroradiology; 2023 Oct; 65(10):1439-1445. PubMed ID: 37247021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
    Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
    J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
    George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
    AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
    Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
    J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma.
    Popp I; Bott S; Mix M; Oehlke O; Schimek-Jasch T; Nieder C; Nestle U; Bock M; Yuh WTC; Meyer PT; Weber WA; Urbach H; Mader I; Grosu AL
    Radiother Oncol; 2019 Jan; 130():121-131. PubMed ID: 30219612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
    Wollring MM; Werner JM; Bauer EK; Tscherpel C; Ceccon GS; Lohmann P; Stoffels G; Kabbasch C; Goldbrunner R; Fink GR; Langen KJ; Galldiks N
    Neuro Oncol; 2023 May; 25(5):984-994. PubMed ID: 36215231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?
    Piroth MD; Liebenstund S; Galldiks N; Stoffels G; Shah NJ; Eble MJ; Coenen HH; Langen KJ
    Mol Imaging; 2013 Sep; 12(6):388-95. PubMed ID: 23981784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging.
    Holodny AI; Makeyev S; Beattie BJ; Riad S; Blasberg RG
    AJNR Am J Neuroradiol; 2010 Jun; 31(6):1042-8. PubMed ID: 20150307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.
    Galldiks N; Stoffels G; Filss CP; Piroth MD; Sabel M; Ruge MI; Herzog H; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2012 Sep; 53(9):1367-74. PubMed ID: 22872742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (
    Kristin Schmitz A; Sorg RV; Stoffels G; Grauer OM; Galldiks N; Steiger HJ; Kamp MA; Langen KJ; Sabel M; Rapp M
    Br J Neurosurg; 2021 Dec; 35(6):736-742. PubMed ID: 31407920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI.
    Werner JM; Stoffels G; Lichtenstein T; Borggrefe J; Lohmann P; Ceccon G; Shah NJ; Fink GR; Langen KJ; Kabbasch C; Galldiks N
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1889-1901. PubMed ID: 31203420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.